CL2024000090A1 - Métodos para tratar la miocardiopatía hipertrófica. - Google Patents

Métodos para tratar la miocardiopatía hipertrófica.

Info

Publication number
CL2024000090A1
CL2024000090A1 CL2024000090A CL2024000090A CL2024000090A1 CL 2024000090 A1 CL2024000090 A1 CL 2024000090A1 CL 2024000090 A CL2024000090 A CL 2024000090A CL 2024000090 A CL2024000090 A CL 2024000090A CL 2024000090 A1 CL2024000090 A1 CL 2024000090A1
Authority
CL
Chile
Prior art keywords
methods
treating hypertrophic
hypertrophic cardiomyopathy
echocardiogram
daily dose
Prior art date
Application number
CL2024000090A
Other languages
English (en)
Spanish (es)
Inventor
Malik Fady
Kupfer Stuart
B Heitner Stephen
Ann ROBERTSON Laura
Meng Lixin
OSMUKHINA Anna
WOHLTMAN Qi
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82850823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2024000090(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CL2024000090A1 publication Critical patent/CL2024000090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
CL2024000090A 2021-07-16 2024-01-10 Métodos para tratar la miocardiopatía hipertrófica. CL2024000090A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163203333P 2021-07-16 2021-07-16
US202263299753P 2022-01-14 2022-01-14
US202263305609P 2022-02-01 2022-02-01
US202263331197P 2022-04-14 2022-04-14
US202263343975P 2022-05-19 2022-05-19

Publications (1)

Publication Number Publication Date
CL2024000090A1 true CL2024000090A1 (es) 2024-08-16

Family

ID=82850823

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2024000090A CL2024000090A1 (es) 2021-07-16 2024-01-10 Métodos para tratar la miocardiopatía hipertrófica.
CL2024001945A CL2024001945A1 (es) 2021-07-16 2024-06-25 Métodos para tratar la miocardiopatía hipertrófica

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024001945A CL2024001945A1 (es) 2021-07-16 2024-06-25 Métodos para tratar la miocardiopatía hipertrófica

Country Status (22)

Country Link
US (4) US20230058927A1 (enExample)
EP (2) EP4370116B1 (enExample)
JP (1) JP2024526334A (enExample)
KR (1) KR20240047359A (enExample)
AU (1) AU2022312506A1 (enExample)
CA (1) CA3225787A1 (enExample)
CL (2) CL2024000090A1 (enExample)
DK (1) DK4370116T3 (enExample)
ES (1) ES3014965T3 (enExample)
FI (1) FI4370116T3 (enExample)
HR (1) HRP20250174T1 (enExample)
HU (1) HUE070699T2 (enExample)
IL (1) IL310140A (enExample)
LT (1) LT4370116T (enExample)
MX (1) MX2024000804A (enExample)
PL (1) PL4370116T3 (enExample)
PT (1) PT4370116T (enExample)
RS (1) RS66640B1 (enExample)
SI (1) SI4370116T1 (enExample)
SM (1) SMT202500098T1 (enExample)
TW (1) TW202320763A (enExample)
WO (1) WO2023288324A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
EP4370116B1 (en) * 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) * 2022-08-04 2025-08-07 サイトキネティックス， インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292695A1 (en) * 2005-06-22 2006-12-28 Roslin Institute Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells
IL322175A (en) * 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
WO2020257609A1 (en) 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4249474A4 (en) 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス， インコーポレイテッド アフィカムテンを調製するための工程
CN119789856A (zh) 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス， インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024050139A1 (en) 2022-09-02 2024-03-07 AnaBios Corporation Therapeutic uses of cardiac myosin inhibitors
EP4604841A1 (en) 2022-10-21 2025-08-27 Prolaio, Inc. System and method of treatment of hypertrophic cardiomyopathy
WO2024097284A1 (en) 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
EP4666076A1 (en) 2023-02-17 2025-12-24 Bristol-Myers Squibb Company Methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels
WO2024182469A1 (en) 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
CN122070481A (zh) 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Also Published As

Publication number Publication date
KR20240047359A (ko) 2024-04-12
RS66640B1 (sr) 2025-04-30
US12370179B1 (en) 2025-07-29
IL310140A (en) 2024-03-01
MX2024000804A (es) 2024-02-06
PL4370116T3 (pl) 2025-04-28
CA3225787A1 (en) 2023-01-19
US20260097021A1 (en) 2026-04-09
HRP20250174T1 (hr) 2025-04-11
CL2024001945A1 (es) 2024-12-06
EP4370116A1 (en) 2024-05-22
US20250177357A1 (en) 2025-06-05
PT4370116T (pt) 2025-03-14
EP4370116B1 (en) 2025-01-15
HUE070699T2 (hu) 2025-06-28
WO2023288324A1 (en) 2023-01-19
ES3014965T3 (en) 2025-04-28
DK4370116T3 (da) 2025-02-03
LT4370116T (lt) 2025-04-10
SI4370116T1 (sl) 2025-04-30
TW202320763A (zh) 2023-06-01
SMT202500098T1 (it) 2025-03-12
EP4548912A2 (en) 2025-05-07
AU2022312506A1 (en) 2024-02-01
FI4370116T3 (fi) 2025-03-04
US20230058927A1 (en) 2023-02-23
EP4548912A3 (en) 2025-07-02
JP2024526334A (ja) 2024-07-17

Similar Documents

Publication Publication Date Title
CL2024001945A1 (es) Métodos para tratar la miocardiopatía hipertrófica
CL2025000127A1 (es) Uso de aficamten para tratar la miocardiopatía hipertrófica no obstructiva.
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2025000195A1 (es) Métodos para el tratamiento de la miocardiopatía hipertrófica obstructiva.
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112022000956A2 (pt) Métodos de tratamento da hiperplasia adrenal congênita
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CR20250160A (es) Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido) carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
CL2024003237A1 (es) Métodos de administración de inhibidores de miosina
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CL2024003328A1 (es) Métodos para el tratamiento de linfoma.
MX2025013173A (es) Regimen de dosificacion de crinecerfont para el tratamiento de la hiperplasia suprarrenal congenita en un sujeto pediatrico
CO2024017693A2 (es) Regímenes de dosis para tratamiento de infección de dengue
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
MX2022002022A (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones.